摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

3-(6-methoxy-benzo[d]isoxazol-3-yl)-benzoic acid | 884850-08-2

中文名称
——
中文别名
——
英文名称
3-(6-methoxy-benzo[d]isoxazol-3-yl)-benzoic acid
英文别名
3-(6-Methoxy-1,2-benzisoxazol-3-yl)benzoic acid;3-(6-methoxy-1,2-benzoxazol-3-yl)benzoic acid
3-(6-methoxy-benzo[d]isoxazol-3-yl)-benzoic acid化学式
CAS
884850-08-2
化学式
C15H11NO4
mdl
——
分子量
269.257
InChiKey
CUNSSESDWHYHEV-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    2.9
  • 重原子数:
    20
  • 可旋转键数:
    3
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    0.07
  • 拓扑面积:
    72.6
  • 氢给体数:
    1
  • 氢受体数:
    5

文献信息

  • METHODS FOR TREATING SPINAL MUSCULAR ATROPHY
    申请人:Paushkin Sergey V.
    公开号:US20110086833A1
    公开(公告)日:2011-04-14
    The present invention provides nucleic acid constructs, methods for identifying and validating compounds that increase the inclusion of exon 7 of SMN2 into mRNA transcribed from the SMN2 gene, compounds and pharmaceutical compositions that increase levels of SMN protein produced from the SMN2 gene, and methods for use thereof in treating of SMA.
    本发明提供了核酸构建物,用于识别和验证增加SMN2基因转录的mRNA中exon 7包含量的化合物的方法,增加从SMN2基因产生的SMN蛋白平的化合物和药物组合物,以及在SMA治疗中使用它们的方法。
  • Compounds for Nonsense Suppression, Use of These Compounds for the Manufacture of a Medicament for Treating Somatic Mutation-Related Diseases
    申请人:Wilde Richard
    公开号:US20080269191A1
    公开(公告)日:2008-10-30
    The present invention relates to methods, compounds, and compositions for treating or preventing diseases associated with nonsense mutations in an mRNA by administering the compounds or compositions of the present invention. More particularly, the present invention relates to methods, compounds, and compositions for suppressing premature translation termination associated with a nonsense mutation in an mRNA.
    本发明涉及使用本发明的化合物或组合物治疗或预防与mRNA中无意义突变相关的疾病的方法、化合物和组合物。更具体地,本发明涉及用于抑制与mRNA中无意义突变相关的早期翻译终止的方法、化合物和组合物。
  • METHODS FOR THE PRODUCTION OF FUNCTIONAL PROTEIN FROM DNA HAVING A NONSENSE MUTATION AND THE TREATMENT OF DISORDERS ASSOCICATED THEREWITH
    申请人:Almstead Neil G.
    公开号:US20110046136A1
    公开(公告)日:2011-02-24
    The present invention relates to functional proteins encoded by nucleic acid sequences comprising a nonsense mutation. The present invention also relates to methods for the production of functional proteins encoded by nucleic acid sequences comprising a nonsense mutation and the use of such proteins for prevention, management and/or treatment of diseases associated with a nonsense mutation(s) in a gene.
    本发明涉及由核酸序列编码的功能性蛋白质,其中包括一个无意义突变。本发明还涉及用于生产由包含无意义突变的核酸序列编码的功能性蛋白质的方法,以及利用这些蛋白质预防、管理和/或治疗与基因中的无意义突变相关的疾病。
  • METHODS FOR THE PRODUCTION OF FUNCTIONAL PROTEIN FROM DNA HAVING A NONSENSE MUTATION AND THE TREATMENT OF DISORDERS ASSOCIATED THEREWITH
    申请人:PTC THERAPEUTICS, INC
    公开号:US20160199357A1
    公开(公告)日:2016-07-14
    The present invention relates to functional proteins encoded by nucleic acid sequences comprising a nonsense mutation. The present invention also relates to methods for the production of functional proteins encoded by nucleic acid sequences comprising a nonsense mutation and the use of such proteins for prevention, management and/or treatment of diseases associated with a nonsense mutation(s) in a gene.
    本发明涉及由包含无意义突变的核酸序列编码的功能蛋白质。本发明还涉及用于生产由包含无意义突变的核酸序列编码的功能蛋白质的方法,并使用这些蛋白质预防、管理和/或治疗与基因中的无意义突变相关的疾病。
  • Methods for the production of functional protein from DNA having a nonsense mutation and the treatment of disorders associated therewith
    申请人:PTC Therapeutics, Inc.
    公开号:EP2387995A1
    公开(公告)日:2011-11-23
    The present invention relates to functional proteins encoded by nucleic acid sequences comprising a nonsense mutation. The present invention also relates to methods for the production of functional proteins encoded by nucleic acid sequences comprising a nonsense mutation and the use of such proteins for prevention, management and/or treatment of diseases associated with a nonsense mutation(s) in a gene.
    本发明涉及由包含无义突变的核酸序列编码的功能性蛋白质。本发明还涉及生产由包含无义突变的核酸序列编码的功能性蛋白质的方法,以及将这种蛋白质用于预防、控制和/或治疗与基因中的无义突变有关的疾病的方法。
查看更多

同类化合物

苯并异恶唑Hsp90抑制剂 苯并[d]异噁唑-7-醇 苯并[d]异噁唑-5-胺 苯并[d]异噁唑-5-磺酰氯 苯并[D]异恶唑-3-甲酸 苯[D]异恶唑-3-醇 羟基伊洛哌酮 甲基6-氨基-1,2-苯并恶唑-3-羧酸酯 甲基4-氨基-1,2-苯并恶唑-3-羧酸酯 环己酮,2,3-二甲基-6-(1-甲基乙基)-,[2R-(2α,3ba,6ba)]-(9CI) 帕潘立酮杂质1 奈氟齐特 四氢-4-[[[4-[[[4-[[(3R)-四氢-3-呋喃基]氧基]-1,2-苯并恶唑-3-基]氧基]甲基]-1-哌啶基]甲基]-2H-吡喃-4-醇 唑尼酰胺-d4 唑尼沙胺钠 唑尼沙胺13C2-15N 唑尼沙胺 呋喃并[3,4:3,4]环丁二烯并[1,2:3,4]环丁二烯并[1,2-d]异噻唑(9CI) 呋喃并[3,4-f][1,2]苯并恶唑 呋喃并[3,4-e][1,2]苯并恶唑 呋喃并[3,2-g][1,2]苯并恶唑 呋喃并[3,2-f]-1,2-苯并异恶唑 呋喃并[2,3-f][1,2]苯并恶唑 呋喃并[2,3-e][1,2]苯并恶唑 叔-丁基(6-溴苯并[D]异噻唑-3-基)氨基甲酯 化合物 T29498 佐尼氯唑 伊潘立酮(R)-羟基杂质 alpha-甲基-3-苯基-1,2-苯并异恶唑-7-乙酸 [1,2]恶唑并[5,4-f][1,2]苯并恶唑 [1,2]恶唑并[5,4-e][2,1,3]苯并恶二唑 [1,1'-联苯基]-3-醇,2'-(5-乙基-3,4-二苯基-1H-吡唑-1-基)- [(3-氨基-1,2-苯并异恶唑-5-基)甲基]氨基甲酸叔丁酯 N,N-二甲基唑尼沙胺杂质 N-甲氧基-N-甲基苯并[d]异恶唑-3-甲酰胺 N-甲基唑尼沙胺 N-乙基苯异恶唑酮四氟硼酸盐 N-[(1,2-苯并恶唑-3-基甲基)磺酰基]乙酰胺 N-(苯并[D]异恶唑-3-基氧基-二甲基氨基-磷酰)-N-甲基-甲胺 N-(6-己酸)唑尼沙胺 7-硝基-1,2-苯并恶唑 7-甲氧基-3-甲基-1,2-苯并恶唑 7-甲基苯并[d]异恶唑-3-醇 7-溴苯并[d]异噁唑 7-溴苯并[D]异恶唑-3(2H)-酮 7-溴-3-氯苯并[D]异恶唑 7-溴-3-(2-氟苯基)苯并[d]异恶唑-6-醇 7-溴-1,2-苯并恶唑-3-胺 7-氯-苯并[d]异恶唑 7-氨基-3-甲基苯并[d]异噁唑-6-醇